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meibomian gland dysfunction (MGD) that allow consis-
tent diagnosis of MGD and are suitable for clinical
studies.
 DESIGN: Development and validation study of grading
scales.
 METHODS: Lid margin and meibomian gland photo-
graphs were taken in the multicenter, prospective
cross-sectional study for MGD and control subjects.
New grading scales for MGD signs (abnormal lid
margin findings of vascularity, plugging of gland ori-
fices, lid margin irregularity, lid margin thickening,
partial glands, and gland dropout) in both upper and
lower eyelids were developed. Three MGD experts, 3
general ophthalmologists, and 3 non-physicians inde-
pendently tested the scales by evaluating photographs.
The levels of interrater and intrarater agreement for
each grading scale were estimated with the use of kappa
statistics.
 RESULTS: Thirty-eight patients with MGD and 20
control subjects were enrolled and photographed. New
grading scales were developed using a total of 226 pho-
tographs. The interrater kappa values for MGD experts
and for general ophthalmologists and non-physicians
with reference to an MGD expert ranged from 0.36 to
0.87 (median of 0.66), 0.41 to 0.73 (0.60), and 0.30
to 0.77 (0.59), respectively. Those for intrarater reli-
ability for 2 MGD experts ranged from 0.49 to 0.93
(0.82).
 CONCLUSIONS: New grading scales for MGD signs
were developed and found to have appropriate inter-
and intrarater reliabilities for grading MGD.
These grading scales are suitable for MGD diagnosis
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T
HE TEAR FILM THAT COVERS THE OCULAR SURFACE
is protected from evaporation by a thin layer of lipid
secreted by the meibomian glands.1 Meibomian
gland dysfunction (MGD) is one of the most common dis-
orders encountered in ophthalmic clinics and is now recog-
nized as a major cause of dry eye syndrome.2–5 It can result
in tear film instability, damage to the ocular surface
epithelium, chronic blepharitis, and contact lens
intolerance.6–10 MGD is commonly characterized by a
chronic, diffuse abnormality of meibomian glands,
terminal duct obstruction, and qualitative or quantitative
changes in the glandular secretion.11 The key signs of
MGD are meibomian gland dropout, altered meibomian
gland secretion, and changes in morphology of the lid
margin. The lid margin abnormalities may become detect-
able with a slit-lamp microscope as the disease progresses.12
Lid margin findings and meibomian gland morphology are
therefore important for diagnosis of MGD. Diagnosis and
quantification of MGD thus require assessment of symp-
toms, altered meibomian gland secretion, changes in lid
morphology, and meibomian gland dropout.12 Evaluation
of meibomian gland expressibility as a dynamic process is
also important. Assessment of the efficacy of treatment
for MGD requires precise evaluation of changes in lid
morphology, meibomian gland dropout, and meibomian
gland expressibility. The ability to perform an objective
evaluation of MGD based on photographs would be useful
as a standardized procedure for multicenter clinical trials.
Grading scales for diagnosis of MGD have been proposed
and adopted in clinical practice.13–18 These scales are based
on assessment of lid margin findings13–15 or of meibomian
glands, with the latter scales being based on the
proportion of meibomian glands showing dropout in only
the lower tarsal plate16,17 or on the number of whole
glands and proportion of partial glands.18 The application
of these existing scales to the clinic is difficult, however,
because there are many grading subdivisions for each sign
or their targets are limited to the lower eyelids. Moreover,
information on grading reliability has been available for
only a few scales. There is thus still an unmet need for reli-
able and widely adoptable grading scales based on125BLISHED BY ELSEVIER INC.
TABLE 1. Background and Clinical Characteristics of Subjects Evaluated for Establishment of Grading Scales for Meibomian Gland
Dysfunction
Characteristic Controls (N ¼ 20) Initial MGD Patients (N ¼ 38) Additional MGD Patients (N ¼ 18)
Sex (male/female) 8/12 13/25 8/10
Age (y) 64.5 6 6.7 66.9 6 15.0 69.1 6 13.2
BUT (s) 6.5 6 1.6 3.4 6 2.1 2.7 6 1.1
Schirmer test value (mm) 16.4 6 9.9 10.6 6 7.2 7.9 6 3.7
Corneal staining scorea 0.0 6 0.0 0.5 6 0.6 0.8 6 0.4
Conjunctival staining scoreb 0.0 6 0.0 0.3 6 0.6 0.4 6 0.5
Telangiectasiac
Upper 0.1 6 0.3 1.7 6 0.9 1.8 6 0.9
Lower 0.1 6 0.2 1.3 6 0.8 1.3 6 0.6
Pluggingd
Upper 0.1 6 0.2 1.3 6 0.7 1.5 6 0.5
Lower 0.0 6 0.0 1.0 6 0.7 1.1 6 0.4
Meiboscoree
Upper 0.4 6 0.5 1.9 6 0.8 2.0 6 0.8
Lower 0.2 6 0.4 1.9 6 0.9 1.6 6 0.8
Meibum gradef
Upper 0.1 6 0.4 1.5 6 0.9 1.6 6 0.5
Lower 0.2 6 0.5 1.6 6 0.7 1.4 6 0.6
Gland dropoutg
Upper 0.1 6 0.3 1.1 6 0.8 2.0 6 0.8
Lower 0.0 6 0.0 1.1 6 0.8 1.7 6 0.8
MGD ¼ meibomian gland dysfunction.
Data are means 6 SD.
aCorneal staining was scored 0-3 for the entire cornea.
bConjunctival staining was scored 0-3 for each of the nasal and temporal conjunctiva and then summed.
cTelangiectasia was assessed on a scale of 0-3.
dPlugging was assessed on a scale of 0-2.
ePartial or complete loss of meibomian glands was scored 0-3 (meiboscore).
fMeibum grade was scored 0-3.
gComplete loss of meibomian glands was scored 0-2.evaluation of both upper and lower eyelids for the consis-
tent diagnosis of MGD.
We have now developed new grading scales for MGD
that can be used by ophthalmologists without special expe-
rience, and we have performed a validation study to
confirm the robustness of these scales. We propose that
these grading scales are suitable for the diagnosis of MGD
or for its evaluation in clinical studies.METHODS
 STUDY DESIGN AND TARGET POPULATION: This study
was conducted at The University of Tokyo Hospital, Itoh
Clinic (Saitama City, Saitama, Japan), and Maeda
Ophthalmic Clinic (Aizuwakamatsu City, Fukushima,
Japan). MGD patients and control subjects were randomly
enrolled from outpatients who visited the 3 medical facil-
ities from December 4, 2012 to December 7, 2013. The126 AMERICAN JOURNAL OFstudy adhered to the tenets of the Declaration of Helsinki
and was prospectively approved by the Institutional Re-
view Board of Tokyo University School of Medicine. All
subjects provided written informed consent before entry
into the study.
The MGD patients were aged >_20 years and were diag-
nosed on the basis of previously described criteria19,20:
(1) at least 1 symptom, such as ocular fatigue, discharge,
foreign body sensation, dryness, uncomfortable sensation,
sticky sensation, pain, epiphora, itching, redness, heavy
sensation, glare, excessive blinking, burning sensation,
and ocular discomfort on arising; (2) at least 1 abnormal
lid margin finding, such as vascular engorgement, anterior
or posterior replacement of the mucocutaneous junction,
and irregular lid margin; and (3) plugged meibomian
gland orifices and poor meibum expressibility in the
target eye. The control subjects had never been
diagnosed with blepharitis or MGD, were aged >_20 years,
and had no history of contact lens wear or eye surgery.
Individuals with severe systemic illness or with squamousSEPTEMBER 2016OPHTHALMOLOGY
TABLE 2. Distribution of Severity for Lid Margin and
Meibomian Gland Findings in Subjects Evaluated for
Establishment of Grading Scales for Meibomian Gland
Dysfunction
Parameter
MGD Patients (N ¼ 38) Controls (N ¼ 20)
Upper Lower Upper Lower
Telangiectasia
0 3 (7.9) 4 (10.8) 17 (89.5) 18 (94.7)
1 14 (36.8) 21 (56.8) 2 (10.5) 1 (5.3)
2 14 (36.8) 8 (21.6) 0 (0) 0 (0)
3 7 (18.4) 4 (10.8) 0 (0) 0 (0)
Missing data 0 1 1 1
Mucocutaneous junction
0 3 (8.3) 4 (11.8) 18 (94.7) 18 (94.7)
1 12 (33.3) 12 (35.3) 1 (5.3) 1 (5.3)
2 11 (30.6) 12 (35.3) 0 (0) 0 (0)
3 10 (27.8) 6 (17.6) 0 (0) 0 (0)
Missing data 2 4 1 1
Irregularity
0 22 (57.9) 19 (50.0) 18 (94.7) 18 (94.7)
1 14 (36.8) 14 (36.8) 1 (5.3) 1 (5.3)
2 2 (5.3) 5 (13.2) 0 (0) 0 (0)
Missing data 0 0 1 1
Plugging
0 5 (13.2) 9 (23.7) 18 (94.7) 19 (100)
1 18 (47.4) 21 (55.3) 1 (5.3) 0 (0)
2 15 (39.5) 8 (21.1) 0 (0) 0 (0)
Missing data 0 0 1 1
Foaming
0 37 (97.4) 34 (91.9) 19 (100) 19 (100)
1 1 (2.6) 2 (5.4) 0 (0) 0 (0)
2 0 (0) 1 (2.7) 0 (0) 0 (0)
Missing data 0 1 1 1
Thickness
0 29 (76.3) 30 (78.9) 19 (100) 19 (100)
1 7 (18.4) 7 (18.4) 0 (0) 0 (0)
2 2 (5.3) 1 (2.6) 0 (0) 0 (0)
Missing data 0 0 1 1
Meiboscore
0 1 (2.7) 0 (0) 12 (60.0) 16 (80.0)
1 11 (29.7) 15 (40.5) 8 (40.0) 4 (20.0)
2 17 (45.9) 10 (27.0) 0 (0) 0 (0)
3 8 (21.6) 12 (32.4) 0 (0) 0 (0)
Missing data 1 1 0 0
MGD ¼ meibomian gland dysfunction.
Data are n (%).cell debris (collarette) around the base of the eyelashes
were excluded.
 CLINICAL ASSESSMENT AND IMAGE COLLECTION: One
eye was selected as the target eye in each subject. Compli-
cations, history of contact lens wear or eye surgery, the
presence of ocular allergy, and concomitant medications
were noted as background information. The subjects were
assessed for lid margin and meibomian gland findings, as
well as for their experience of subjective symptoms.
Lid margin findings were evaluated for the upper and
lower eyelids with the use of a slit-lamp microscope. Tel-
angiectasia was assessed on a scale from 0 to 3: 0 ¼ no
findings; 1 ¼ mild telangiectasia; 2 ¼ moderate telangiec-
tasia or redness; 3 ¼ severe telangiectasia or redness.
Mucocutaneous junction was assessed on a scale from
0 to 3: 0 ¼ Marx line (ML) courses on the skin side of
the meibomian orifice (MO) line and does not touch
MOs at all; 1 ¼ parts of ML touch MOs; 2 ¼ ML courses
through MOs; 3 ¼ ML courses along the eyelid margin
side of MOs.21 Irregularity, plugging, foaming, and thick-
ness were assessed on a scale from 0 to 2: 0 ¼ no findings;
1 ¼ mild findings; 2 ¼ severe findings.
Corneal and conjunctival staining were scored from
0 to 9.22 The tear film breakup time (BUT) was
measured 3 times consecutively after the instillation of
fluorescein, and the mean value was adopted. Tear fluid
production was evaluated with the Schirmer test without
anesthesia.
Meibomian glands were evaluated for the upper and
lower lids with the use of a noncontact meibography system
attached to a slit-lamp microscope. Partial or complete loss
of meibomian glands was scored on a scale from 0 to 3
(meiboscore), as described previously.23 The extent of
meibomian gland dropout was determined on a scale
from 0 to 2 based on the number of affected glands: 0 ¼
none; 1 ¼ small number; 2 ¼ large number.
The degree of ease with which meibum could be
expressed at the central area of both upper and lower eyelid
was evaluated semiquantitatively on a scale from 0 to 3: 0¼
clear meibum readily expressed; 1 ¼ cloudy meibum
expressed with mild pressure; 2¼ cloudy meibum expressed
with more than moderate pressure; 3 ¼ meibum could not
be expressed even with strong pressure.16
Images of lid margins and orifices of meibomian glands at
the upper and lower eyelids of 1 eye were obtained with a
digital camera and meibography system attached to a slit-
lamp microscope (SL-D701 DC4 BG-5; Topcon Japan,
Tokyo, Japan).23 The images of the lid margins and those
of meibomian glands were both acquired at 103magnifica-
tion for the full length of each eyelid within a single photo-
graph. Four images (2 of each eyelid) were collected for
each subject.
 NEW GRADING SYSTEM: We developed grading scales
for MGD with the use of printed images. All imagesVOL. 169 RELIABLE GRADING SCALES FOR MEwere acquired by an ophthalmologist (R.A. or R.S.)
with a specialty in MGD. Four signs for lid margin find-
ings detected with a slit-lamp microscope and 2 signs of
meibomian glands detected by meibography were selected
for development of the grading scales. Three MGD ex-
perts (R.A., R.S., and S.F.), each participating at a
different institution, developed draft grading scales for127IBOMIAN GLAND DYSFUNCTION
FIGURE 1. Distribution of the severity of meibum grade (Left) and meibomian gland dropout (Right) for the enrolled meibomian
gland dysfunction patients (n[ 38). Meibum grade was scored on a scale of 0-3 for each of the upper and lower eyelids and then
summed. Meibomian gland dropout was scored on a scale of 0-2 for each of the upper and lower eyelids and then summed.
TABLE 3. Proposed Grading Scales for Meibomian Gland Dysfunction
Abnormal Lid Margin Findings of Vascularity
0 ¼ No or slight redness in lid margin conjunctiva and no telangiectasia crossing meibomian gland orifices
1 ¼ Redness in lid margin conjunctiva and no telangiectasia crossing meibomian gland orifices
2 ¼ Redness in lid margin conjunctiva and telangiectasia crossing meibomian gland orifices with a distribution of less than half of the full
length of the lid
3¼Redness in lidmargin conjunctiva and telangiectasia crossingmeibomian gland orifices with a distribution of half or more of the full length
of the lid
Plugging of Gland Orifices
0 ¼ No plugging of gland orifices
1 ¼ Fewer than 3 pluggings of gland orifices
2 ¼ Three or more pluggings of gland orifices with a distribution of less than half of the full length of the lid
3 ¼ Three or more pluggings of gland orifices with a distribution of half or more of the full length of the lid
Lid Margin Irregularity
0 ¼ No lid margin irregularity
1 ¼ Fewer than 3 lid margin irregularities with shallow notching
2 ¼ Three or more lid margin irregularities or deep notching
Lid Margin Thickening
0 ¼ No lid margin thickening
1 ¼ Lid margin thickening with or without localized rounding
2 ¼ Lid margin thickening with diffuse rounding
Partial Glands
0 ¼ No partial glands
1 ¼ Fewer than 3 partial glands
2 ¼ Three or more partial glands and fewer than 3 partial glands with loss of half or more of the full length
3 ¼ Three or more partial glands with loss of half or more of the full length
Gland Dropout
0 ¼ No gland dropout
1 ¼ Fewer than 3 gland dropouts
2 ¼ Three or more gland dropoutsMGD with key conceptual components based on morpho-
logic and anatomic criteria described in previous re-
views.13,14 These draft grading scales were then128 AMERICAN JOURNAL OFevaluated with a preliminary validation test in which
each of the 3 MGD experts classified the printed images
independently according to the draft scales, and theSEPTEMBER 2016OPHTHALMOLOGY
FIGURE 2. Representative images of lid margin findings of vascularity. Grade 0 (Upper left), grade 1 (Upper right), grade 2 (Middle
left), and grade 3 (Middle right) are based on the degree of redness in the lid margin and the distribution of telangiectasia crossing
meibomian gland orifices. Note that telangiectasia is observed but does not cross the gland orifices in half of the eyelid in grade 2 (Bot-
tom left), whereas it crosses the gland orifices in half or more of the eyelid in grade 3 (Bottom right).consistency for each scale was determined. The 3 experts
then reviewed the results and adjusted the grading scales
accordingly. The 3 experts then reviewed the results and
adjusted the grading scales accordingly with the advice of
another expert. The final versions proceeded to the
validation test as the proposed grading scales.
 VALIDATION TESTING: Validation testing was
performed to evaluate the robustness of the proposed
grading scales after an interval of >2 weeks since their
development. The raters received printed images of theVOL. 169 RELIABLE GRADING SCALES FOR MEupper and lower eyelids of the original 58 subjects together
with printed grading scales and representative images. Each
printed image had a randomly assigned number for analysis.
Raters individually classified each image according to the
grading scales. The test was performed by each rater at a
separate site. After the test, the assigned numbers of the
classified images for each grading scale were recorded for
statistical analysis.
Interrater and intrarater reliability. Three MGD experts
(R.A., R.S., and S.F.) performed the validation test, and129IBOMIAN GLAND DYSFUNCTION
FIGURE 3. Representative images of plugging of gland orifices. Grade 0 (Upper left), grade 1 (Upper right), grade 2 (Middle left),
and grade 3 (Middle right) are based on the number and distribution of abnormal findings for meibomian gland orifices such as capping,
pouting, and ridge. Arrows indicate plugging (Upper right). Plugging is apparent but shows a distribution of less than half of the lid
length in grade 2 (Bottom left), whereas it is distributed along half or more of the lid length in grade 3 (Bottom right).consistency among their results for each grading scale was
evaluated.
Two of the MGD experts who participated in the deter-
mination of interrater reliability (R.A. and S.F.) performed
the test a second time after an interval of >2 weeks. Con-
sistency between the results of the first and second tests for
each grading scale was evaluated.
Effect of clinical experience. Three general ophthalmolo-
gists (non–MGD experts) who had been certified for 3, 5,
or 8 years, as well as 3 non-physicians, also performed the130 AMERICAN JOURNAL OFvalidation test. An introduction and explanation of the
grading scales were given before the test by an MGD
expert (R.A.). Consistency between the results for each
group of raters and those for an MGD expert (first test
performance by R.A.) was evaluated as interrater
reliability.
Additional validation. For confirmation of the intrarater
and interrater reliability of the grading scales, 2 MGD ex-
perts (N.M. and Tohru Sakimoto [Nihon University])
who did not contribute to their development performedSEPTEMBER 2016OPHTHALMOLOGY
FIGURE 4. Representative images of lid margin irregularity. Grade 0 (Top left), grade 1 (Middle left), and grade 2 (Bottom left) are
based on the number of irregularities and the form of notching. Notching is not observed in grade 0 (Top right), is shallow in grade 1
(Middle right, arrow), and is deep in grade 2 (Bottom right, arrowheads).the validation test as described above but with images of
the upper and lower eyelids of 18 additional MGD pa-
tients that were not used for scale development. Those
images of additional MGD patients were obtained at
Itoh Clinic.
 DIAGNOSTIC ABILITY OF THE PROPOSED GRADING
SCALES: For evaluation of the diagnostic ability of the pro-
posed grading scales, the MGD patients and control sub-
jects were classified on the basis of the validation test
results for an MGD expert (first test performance by
R.A.). The total score of the upper and lower eyelids wasVOL. 169 RELIABLE GRADING SCALES FOR MEused for the calculation. Receiver operating characteristic
(ROC) curves and the area under the curve (AUC) were
calculated for each grading scale.
 STATISTICAL ANALYSIS: Data were collected into an
Excel 2010 worksheet and were analyzed with the use of
SAS version 9.2 software (SAS Institute, Cary, North Car-
olina, USA). Weighted kappa values and 95% confidence
intervals (CIs) for each grading scale were calculated to
evaluate consistency in test performance. Median values
were used to summarize the results for weighted kappa
values for each test.131IBOMIAN GLAND DYSFUNCTION
FIGURE 5. Representative images of lid margin thickening. Grade 0 (Upper left), grade 1 (Upper right), and grade 2 (Bottom left)
are based on the presence of thickening and rounding.RESULTS
THIRTY-EIGHT MGD PATIENTS (13 MEN AND 25 WOMEN;
mean age6 SD, 66.96 15.0 years) and 20 control subjects
(8 men and 12 women; 64.5 6 6.7 years) were eventually
enrolled. All subjects underwent clinical assessment and
image collection, and their clinical characteristics are
shown in Table 1.
For the MGD patients, lid margin and meibomian gland
findings encompassed the range of severity levels and
appeared to reflect the distribution of findings encountered
in the clinic (Table 2, Figure 1). For the control subjects,
almost all findings were normal (Table 2). With the excep-
tion of 6 missing images, 4 images acquired from each sub-
ject (total of 226 images) were used to develop the new
grading system.
 NEW GRADING SYSTEM: We developed 6 grading scales
for MGD based on images of the upper and lower eyelids
of 38 MGD patients and 20 control subjects (Table 3,
Supplemental Figure; Supplemental Material available at
AJO.com). Abnormal lid margin findings of vascularity
(Figure 2), plugging of gland orifices (Figure 3), lid margin
irregularity (Figure 4), and lid margin thickening (Figure 5)132 AMERICAN JOURNAL OFwere evaluated in the full-length images of each eyelid ob-
tained with a slit-lamp microscope. Partial glands
(Figure 6) and gland dropout (Figure 7) were evaluated
by noncontact meibography for meibomian glands in the
middle two-thirds of each eyelid, given that it is difficult
to capture and examine glands at the ends of each eyelid
in a single photograph (Figure 6).
Each grading scale is based on specific features.
Abnormal lid margin findings of vascularity are based on
2 key components: the degree of redness at the lid margin
and the distribution of telangiectasia crossing meibomian
gland orifices. Plugging of gland orifices includes abnormal
findings for meibomian gland orifices such as capping, pout-
ing, and ridge and is evaluated on the basis of the number
and distribution of these abnormal findings. Lid margin ir-
regularity is evaluated on the basis of the number of lid
margin irregularities and form of notching. Lid margin
thickening is evaluated based on the presence of thick-
ening and rounding. Partial glands are defined as meibo-
mian glands showing partial loss from the orifice or fornix
and are evaluated on the basis of their number and length
(Figure 6). Gland dropout is evaluated on the basis of the
number of meibomian glands with complete loss from
orifice to fornix (Figure 7).SEPTEMBER 2016OPHTHALMOLOGY
FIGURE 6. Representative images of partial glands. Grade 0 (Upper left), grade 1 (Upper right), grade 2 (Middle left), and grade 3
(Middle right) are based on the number and extent of partial meibomian glands, which are defined as glands with partial loss between
the orifice and fornix. The scheme illustrates the definition of partial glands and gland dropout (Bottom), both of which are assessed
over the middle two-thirds of each eyelid. VALIDATION TESTING: Evaluation of interrater reli-
ability for performance of a validation test for the 6
grading scales by 3 MGD experts yielded a rangeVOL. 169 RELIABLE GRADING SCALES FOR ME(median) of weighted kappa values of 0.36-0.81 (0.68)
for the upper eyelid and 0.57-0.87 (0.65) for the lower
eyelid, as shown in Table 4, referred with agreement.24133IBOMIAN GLAND DYSFUNCTION
FIGURE 7. Representative images of gland dropout. Grade 0 (Upper left), grade 1 (Upper right), and grade 2 (Bottom left) are based
on the number of meibomian glands showing complete loss from orifice to fornix.The range (median) of weighted kappa values for eval-
uation of intrarater reliability for 2 MGD experts who
performed the test twice was 0.49-0.92 (0.79) for the
upper eyelid and 0.67-0.93 (0.85) for the lower eyelid
(Table 4). With regard to the effect of clinical experi-
ence, evaluation of interrater reliability yielded a range
(median) of weighted kappa values of 0.42-0.66 (0.59)
for the upper eyelid and 0.41-0.73 (0.65) for the lower
eyelid for 3 general ophthalmologists and of 0.35-0.68
(0.53) for the upper eyelid and 0.30-0.77 (0.63) for
the lower eyelid for 3 non-physicians (Table 4). For
confirmation of the reliability of the grading scales,
the validation test was performed by 2 additional
MGD experts who did not contribute to their develop-
ment and with images obtained from a different group
of 18 MGD patients that were also not used for scale
development. The range (median) of weighted kappa
values for evaluation of intrarater reliability for the 2
additional MGD experts who performed the test twice
was 0.47-0.92 (0.65) for the upper eyelid and 0.49-
0.91 (0.80) for the lower eyelid (Table 5). The evalua-
tion of interrater reliability yielded a range (median) of
weighted kappa values of 0.49-0.92 (0.53) for the upper
eyelid and 0.30-0.74 (0.51) for the lower eyelid
(Table 5).134 AMERICAN JOURNAL OF DIAGNOSTIC ABILITY OF THE PROPOSED GRADING
SCALES: Finally, with regard to the diagnostic ability
of the proposed grading scales, generation of ROC
curves revealed that gland dropout showed the greatest
AUC with a value of 0.78 (95% CI, 0.66-0.90),
followed by partial glands (AUC ¼ 0.72; 95% CI,
0.58-0.86), plugging of gland orifices (AUC ¼ 0.70;
95% CI, 0.55-0.85), lid margin thickening (AUC ¼
0.69; 95% CI, 0.54-0.84), lid margin irregularity
(AUC ¼ 0.59; 95% CI, 0.46-0.73), and abnormal lid
margin findings of vascularity (AUC ¼ 0.54; 95% CI,
0.37-0.71) (Figure 8).DISCUSSION
WE HAVE HEREIN DEVELOPED 6 NEW GRADING SCALES FOR
typical clinical findings in MGD and have evaluated the
reliability of these scales with the use of 226 images ob-
tained from 58 subjects. The new grading scales were based
on real clinical findings and were found to be robust and to
show better than moderate agreement in most instances on
validation testing. Whereas evaluation of dynamic features
of meibomian gland function such as meibum expressibilitySEPTEMBER 2016OPHTHALMOLOGY
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VOL. 169 RELIABLE GRADING SCALES FOR MEand color is informative with regard to assessment of MGD,
such evaluation is difficult to record as dynamic results. The
new grading scales with representative images should thus
prove helpful for the diagnosis of MGD in a consistent
manner and be particularly useful for the evaluation of
MGD in multicenter clinical studies.
The reliability of the new grading scales is likely attribut-
able at least in part to the clear definitions and descriptions
on which they are based, with avoidance of imprecise terms
such as mild, moderate, or severe. The scales thus allow an
objective classification of morphologic and anatomic find-
ings. Moreover, the grading scales are applicable to both
upper and lower eyelids. Given that the degree of morpho-
logic change of meibomian glands has been found to differ
between the upper and lower eyelids in MGD patient and
dry eye patient populations, examination of both eyelids
is essential for proper evaluation of the pathologic condi-
tion of such individuals.25,26
The new grading scales showed a high level of consis-
tency among MGD experts, general ophthalmologists,
and non-physicians. These findings indicate that any
ophthalmologist should be able to diagnose MGD and
classify its severity in a consistent manner with the
grading scales. This ability is likely to prove especially
useful in clinical studies or trials, with the grading scales
allowing investigators at different sites to enroll appro-
priate subjects and to evaluate the efficacy of medica-
tion in a consistent manner and thus allowing the
results obtained at the different sites to be compared
directly.
Our evaluation of the new grading scales revealed that
consistency among raters was lowest for plugging of gland
orifices and lid margin irregularity. Plugging of gland ori-
fices is usually assessed by determining the expressibility
of meibum, and lid margin irregularity is usually assessed
with a slit-lamp microscope by changing the angle of the
light relative to the patient’s eyelids. The consistent
grading of these clinical findings based only on images
might thus be expected to be more difficult than that for
the other assessed signs.
We also investigated the diagnostic ability of the new
grading scales for the enrolled MGD patients and con-
trol subjects. Construction of ROC curves and calcula-
tion of AUC values revealed that the scales for both
partial glands and gland dropout showed sufficient diag-
nostic ability, suggesting that both signs are MGD spe-
cific and should be evaluated separately. These
findings are consistent with the results of a previous
study.20 On the other hand, the AUC for abnormal
lid margin findings of vascularity was lowest among
the grading scales. The grading scale for this sign ap-
pears to be affected not only by MGD but also by aging
or other factors, such as workplace exposure to dust par-
ticles, urban living, and cosmetics.15 As far as we are
aware, this is the first study to evaluate diagnostic ability
of partial glands and gland dropout separately on the135IBOMIAN GLAND DYSFUNCTION
TABLE 5. Weighted Kappa Values and 95% Confidence Intervals for Intrarater and Interrater Variability in Additional Evaluation of
Grading Scales for Meibomian Gland Dysfunction
Grading Scale
Intrarater Interrater
Additional MGD Expert 1 (N.M.) Additional MGD Expert 2 (T.S.) Additional MGD Experts
Upper Lower Upper Lower Upper Lower
Abnormal lid margin
findings of vascularity
0.92 (0.83-0.99) 0.91 (0.83-0.99) 0.66 (0.52-0.80) 0.84 (0.73-0.95) 0.92 (0.83-0.99) 0.58 (0.43-0.73)
Plugging of gland orifices 0.74 (0.61-0.88) 0.84 (0.73-0.95) 0.47 (0.31-0.66) 0.70 (0.57-0.83) 0.50 (0.33-0.66) 0.30 (0.15-0.45)
Lid margin irregularity 0.82 (0.65-0.99) 0.80 (0.67-0.93) 0.64 (0.31-0.97) 0.49 (0.26-0.72) 0.49 (0.30-0.68) 0.72 (0.54-0.91)
Lid margin thickening 0.52 (0.34-0.70) 0.49 (0.32-0.66) 0.50 (0.29-0.71) 0.80 (0.67-0.94) 0.55 (0.39-0.72) 0.41 (0.25-0.56)
Partial glands 0.72 (0.60-0.85) 0.80 (0.66-0.93) 0.50 (0.34-0.66) 0.74 (0.61-0.87) 0.52 (0.37-0.67) 0.43 (0.28-0.57)
Gland dropout 0.82 (0.71-0.93) 0.81 (0.68-0.94) 0.49 (0.33-0.65) 0.82 (0.71-0.94) 0.54 (0.40-0.68) 0.74 (0.61-0.87)
MGD ¼ meibomian gland dysfunction.
Kappa values of<0.01, 0.01-0.20, 0.21-0.40, 0.41-0.60, 0.61-0.80, and 0.81-1.00 correspond to poor, slight, fair, moderate, substantial, and
almost-perfect agreement, respectively.24
FIGURE 8. Receiver operating characteristic curves for the 6
new grading scales.basis of AUC values. A previous study examined the
diagnostic ability of the total score for 4 eyelid signs
(vascular engorgement, plugged meibomian gland ori-
fices, irregular lid margin, and anterior or posterior
replacement of the mucocutaneous junction) by calcula-
tion of AUC values.21 We evaluated the AUC for each
of these signs (with the exception of mucocutaneous
junction) separately. These results can provide useful
information for interpretation of scores obtained with
the grading scales in clinical practice.
In the present study, we evaluated only 1 eye of each
subject; therefore we are unable to address the bilaterality136 AMERICAN JOURNAL OFof MGD characteristics. MGD is one of the most com-
mon causative conditions of dry eye.27 Application of
the grading scales to both eyes of an individual would
provide information on the bilaterality of MGD or dry
eye.
There is a general consensus regarding the definition of
MGD severity based on meibum score, symptoms, and lid
margin findings.11,14 However, the ability to evaluate
MGD severity more accurately with reliable objective
scales based on standardized criteria is needed. Our
proposed new grading system can be used to define MGD
severity. It should be possible to classify MGD patients
according to disease severity with the use of such a
grading system, including multiple static and dynamic
evaluation procedures.
There are some limitations to the present study. First,
the study was based on static evaluation of photographs
and thus did not take into account dynamic observations
such as meibum expressibility, including meibum quality
and quantity. Given that evaluation of meibum expressi-
bility is one of the most informative procedures regarding
the pathogenesis of MGD, movie-based assessment of
meibum expressibility and other dynamic features should
be performed in the future. Second, the new grading
scales were developed with the use of images obtained
in a cross-sectional analysis. We were therefore not able
to evaluate whether they are suitable for detection of
changes in clinical findings. It will be necessary to confirm
that the grading scales are appropriate for evaluation of
medical treatment in longitudinal studies. Third, we
also evaluated the reliability of the grading scales with
the same set of images. Given that plugging of gland ori-
fices and lid margin irregularity can be assessed accurately
only by physical examination with observation in 3 di-
mensions, the assessment of these signs from 2-dimen-
sional images may be problematic. There is thus stillSEPTEMBER 2016OPHTHALMOLOGY
room for improvement of the proposed clinical scoring for
MGD, but, despite its basis in static evaluation, it is
potentially sufficient for clinical application. Its further
improvement will be required for it to become a standard
procedure for MGD diagnosis.VOL. 169 RELIABLE GRADING SCALES FOR MEIn conclusion, we have developed new grading scales for
MGD that are sufficiently reliable for use by any ophthal-
mologist. Further studies are warranted to determine
whether the grading scales are suitable for evaluation of
the efficacy of MGD management.FUNDING/SUPPORT: THIS STUDY WAS SUPPORTED BY SANTEN PHARMACEUTICAL CO LTD (OSAKA, JAPAN). THE SPONSOR
participated in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article
for publication. Financial disclosures: Reiko Arita has received personal fees from Santen Pharmaceutical Co Ltd (Osaka, Japan), Otsuka Pharmaceutical
Co Ltd (Tokushima, Japan), Kiribai Chemical Co Ltd (Osaka, Japan), Kao Corporation (Tokyo, Japan), Japan Focus Company Ltd (Tokyo, Japan),
TOPCON Japan (Tokyo, Japan), and TearScience (Morrisville, NC). Naoyuki Morishige has received personal fees from Santen Pharmaceutical Co
Ltd (Osaka, Japan), Otsuka Pharmaceutical Co Ltd (Tokushima, Japan), Kao Corporation (Tokyo, Japan), Japan Focus Company Ltd (Tokyo, Japan),
Pfizer Japan Inc (Tokyo, Japan), Wakamoto Co Ltd (Tokyo, Japan), and Astellas Pharma Inc (Tokyo, Japan). Shima Fukuoka has received personal
fees from Santen Pharmaceutical Co Ltd (Osaka, Japan). Izumi Minoura, Kei Asai, Tateki Goto, Takahiro Imanaka, and Masatsugu Nakamura are em-
ployees of Santen Pharmaceutical Co Ltd (Osaka, Japan). The following author has no financial disclosures: Rika Shirakawa. All authors attest that
they meet the current ICMJE criteria for authorship.REFERENCES
1. MishimaS,MauriceDM.Theoily layer of the tearfilmandevap-
oration from the corneal surface. Exp Eye Res 1961;1:39–45.
2. Lemp MA. Report of the National Eye Institute/Industry
Workshop on Clinical Trials in Dry Eyes. CLAO J 1995;
21(4):221–232.
3. Mathers WD. Ocular evaporation in meibomian gland
dysfunction and dry eye. Ophthalmology 1993;100(3):347–351.
4. Shimazaki J, Sakata M, Tsubota K. Ocular surface changes
and discomfort in patients with meibomian gland dysfunc-
tion. Arch Ophthalmol 1995;113(10):1266–1270.
5. Lee SH, Tseng SC. Rose bengal staining and cytologic char-
acteristics associated with lipid tear deficiency. Am J Ophthal-
mol 1997;124(6):736–750.
6. Mathers WD, Shields WJ, Sachdev MS, et al. Meibomian
gland dysfunction in chronic blepharitis. Cornea 1991;
10(4):277–285.
7. Korb DR, Henriquez AS. Meibomian gland dysfunction and
contact lens intolerance. J Am Optom Assoc 1980;51(3):
243–251.
8. Henriquez AS, Korb DR. Meibomian glands and contact lens
wear. Br J Ophthalmol 1981;65(2):108–111.
9. Zengin N, Tol H, Gunduz K, et al. Meibomian gland dysfunc-
tion and tear film abnormalities in rosacea. Cornea 1995;
14(2):144–146.
10. Ong BL. Relation between contact lens wear and meibomian
gland dysfunction. Optom Vis Sci 1996;73(3):208–210.
11. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The
International Workshop on Meibomian Gland Dysfunction:
Report of the Definition and Classification Subcommittee.
Invest Ophthalmol Vis Sci 2011;52(4):1930–1937.
12. Tomlinson A, Bron AJ, Korb DR, et al. The International
Workshop on Meibomian Gland Dysfunction: Report of
the Diagnosis Subcommittee. Invest Ophthalmol Vis Sci
2011;52(4):2006–2049.
13. BronAJ, Benjamin L, SnibsonGR.Meibomian gland disease.
Classification and grading of lid changes. Eye 1991;5(4):
395–411.
14. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clin-
ical scheme for description, diagnosis, classification and
grading. Ocul Surf 2003;1(3):107–126.15. Hykin PG, Bron AJ. Age-related morphological changes in
lid margin and meibomian gland anatomy. Cornea 1992;
11(4):334–342.
16. Shimazaki J, Goto E, OnoM, et al. Meibomian gland dysfunc-
tion in patients with Sjogren syndrome. Ophthalmology 1998;
105(8):1485–1488.
17. Pflugfelder SC, Tseng SC, Sanabria O, et al. Evaluation of
subjective assessments and objective diagnostic tests for diag-
nosing tear-film disorders known to cause ocular irritation.
Cornea 1998;17(1):38–56.
18. Nichols JJ, Berntsen DA, Mitchell GL, Nichols KK. An
assessment of grading scales for meibography images. Cornea
2005;24(4):382–388.
19. Amano S, Arita R, Kinoshita S, et al. The Japan Dry
Eye Society Meibomian Gland Dysfunction Working
Group. Definition and diagnostic criteria for meibomian
gland dysfunction. Atarashii Ganka (J Eye) 2010;27(5):
627–631.
20. Arita R, Itoh K, Maeda S, et al. Proposed diagnostic criteria
for obstructive meibomian gland dysfunction. Ophthalmology
2009;116(11):2058–2063.
21. Yamaguchi M, Kutsuna M, Uno T, et al. Marx line: fluores-
cein staining line on the inner lid as indicator of meibomian
gland function. Am J Ophthalmol 2006;141(4):669–675.
22. Van Bijsterveld OP. Diagnostic tests in the sicca syndrome.
Arch Ophthalmol 1969;82(1):10–14.
23. Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared
meibography to document age-related changes of the meibo-
mian glands in a normal population. Ophthalmology 2008;
115(5):911–915.
24. Landis JR, Koch GC. The measurement of observer agree-
ment for categorical data. Biometrics 1977;33:159–174.
25. Pult H, Riede-Pult BH, Nichols JJ. Relation between upper
and lower lids’ meibomian gland morphology, tear film, and
dry eye. Optom Vis Sci 2012;89(3):E310–E315.
26. Koh S, Ikeda C, Fujimoto H, et al. Regional differences in tear
film stability and meibomian glands in patients with aqueous-
deficient dry eye. Eye Contact Lens 2016;42(4):250–255.
27. LempMA, Crews LA, BronAJ, Foulks GN, Sullivan BD. Dis-
tribution of aqueous-deficient and evaporative dry eye in a
clinic-based patient cohort: a retrospective study. Cornea
2012;31(5):472–478.137IBOMIAN GLAND DYSFUNCTION
